Die nächste Generation - 500 Beiträge pro Seite
eröffnet am 08.11.06 22:10:10 von
neuester Beitrag 14.03.07 21:15:18 von
neuester Beitrag 14.03.07 21:15:18 von
Beiträge: 4
ID: 1.093.121
ID: 1.093.121
Aufrufe heute: 0
Gesamt: 1.259
Gesamt: 1.259
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 7532 | |
| vor 1 Stunde | 7199 | |
| vor 1 Stunde | 4575 | |
| vor 1 Stunde | 3991 | |
| 02.02.07, 20:48 | 2684 | |
| vor 1 Stunde | 2457 | |
| vor 1 Stunde | 1876 | |
| vor 1 Stunde | 1706 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.735,00 | +1,25 | 201 | |||
| 2. | 7. | 0,3100 | -67,71 | 110 | |||
| 3. | 4. | 0,2110 | +7,11 | 100 | |||
| 4. | 2. | 159,46 | -1,61 | 52 | |||
| 5. | 38. | 2,5545 | +8,70 | 47 | |||
| 6. | 9. | 6,6570 | +0,14 | 41 | |||
| 7. | 12. | 0,1645 | -5,46 | 38 | |||
| 8. | 5. | 4,1525 | -0,48 | 34 |
Feedback
Neuer Name, neue Produkte, neues Glück ?
Die US-Firma Tapestry hat einen vielversprechenden Neufang gewagt.
Die kleine US-Firma Tapestry Pharmaceuticals kennt hierzulande kaum ein Anleger. Kein Wunder, schließlich trägt das Unternehmen diesen Namen erst seit Mai 2004. Davor firmierte Tapestry unter NaPro Biotherapeutics, ein name, der Investoren schon eher ein begriff sein dürfte. Nach wie vor liegt der Fokus auf der Entwicklung neuartiger Krebsmedikamente. Von seinem ursprünglichen Geschäft hat Tapestry sich jedoch verabschiedet.
Zuviel Wettbewerb
Ursprünglich war das Geschäft auf der Entwicklung von Paclitaxel ausgerichtet. Das so genannte Taxan, ( siehe unten die Erklärung) das heute syntetisch hergestellt wird und originär aus der Rinde der pazifischen Eibe stammt, wird seit rund zehn Jahren im Rahmen der Chemotherapie in der Krebsbehandlung eingesetzt.
Doch durch einen hohen Konkurrenzdruck und günstige Nachahmerpräparate kamen die Preise für Paclitaxel unter Druck. Zudem entwickelten immer mehr Patienten Resistenzen gegen das Mittel oder hatten mit den teils schwerwiegenden Nebenwirkungen zu kämpfen. NaPro/Tapestry entschied sich deshalb, sein Paclitaxel-Geschäft zu verkaufen. Im Dezember 2003 wurden alle diese Aktivitäten für rund 70 Millionen Dollar an Mayne Pharma veräußert.
Neuer Schwerpunkt
Seitdem widmet sich Tapestry der Entwicklung einer neuen Generation von Taxanen, die nicht nur wirksamer sein sollen, sondern auch weniger Nebenwirkungen aufweisen und bei Patienten angewendet werden können, die auf einen Behandlung mit Paclitaxel und vergleichbaren Präparaten aufgrund von resistenzen nicht mehr ansprechen. Der aussichtsreiche Produktkandidat von Tapestry trägt den Forschungsnamen TPI 287. In verschiedenen klinischen Studien wird derzeit dessen potenzial bei der Behandlung von Lungen-, Brust- und Prostatakrebs ausgelotet. Bis ende des Jahres sollen die ergebnisse der Phase-I-Tests veröffentlicht werden. Fallen diese positiv aus, dürfte dies der Aktie einen ordentlichen Schub geben.
Hohes Risioko, große Chance
Der Markt für Taxane zur Krebstherapie wird von Experten auf rund drei milliarden Dollar geschätzt. Verläuft die Entwicklung der produktkandidaten weiter positiv, dürfte sich Tapestry von diesen Kuchen eine gute Scheibe abschneiden. Allerdings befinden sich die Wirkstoffe noch in einem sehr frühen Entwicklundsstadium, was die Gefahr von rückschlägen deutlich erhöht. die Aktie ist deshalb nur für Anleger mit extremen hoher Risikobereitschaft geeignet.
WKN: A0JC4R
ISIN: US8760312046
Kürzel: TPPH ( New York)
MK: 31,4 Mio. US-$
Akt. Kurs: 1,48 Euro
Videotext: BR 542
Quelle: Der Aktionär/ Ausgabe 46
Taxane: Als Taxanen bezeichnet man chemische Substanzen, die bösartige Zellen schädigen und deren Wachstum verhindern. Taxane werden zur Bekämpfung von Krebs seit rund 10 jahren in der Chemotherapie verwendet. Paclitaxel, das aus der Rinde der pazifischen Eibe gewonnen wird, wurde als erstes Taxan genutzt.
Die US-Firma Tapestry hat einen vielversprechenden Neufang gewagt.
Die kleine US-Firma Tapestry Pharmaceuticals kennt hierzulande kaum ein Anleger. Kein Wunder, schließlich trägt das Unternehmen diesen Namen erst seit Mai 2004. Davor firmierte Tapestry unter NaPro Biotherapeutics, ein name, der Investoren schon eher ein begriff sein dürfte. Nach wie vor liegt der Fokus auf der Entwicklung neuartiger Krebsmedikamente. Von seinem ursprünglichen Geschäft hat Tapestry sich jedoch verabschiedet.
Zuviel Wettbewerb
Ursprünglich war das Geschäft auf der Entwicklung von Paclitaxel ausgerichtet. Das so genannte Taxan, ( siehe unten die Erklärung) das heute syntetisch hergestellt wird und originär aus der Rinde der pazifischen Eibe stammt, wird seit rund zehn Jahren im Rahmen der Chemotherapie in der Krebsbehandlung eingesetzt.
Doch durch einen hohen Konkurrenzdruck und günstige Nachahmerpräparate kamen die Preise für Paclitaxel unter Druck. Zudem entwickelten immer mehr Patienten Resistenzen gegen das Mittel oder hatten mit den teils schwerwiegenden Nebenwirkungen zu kämpfen. NaPro/Tapestry entschied sich deshalb, sein Paclitaxel-Geschäft zu verkaufen. Im Dezember 2003 wurden alle diese Aktivitäten für rund 70 Millionen Dollar an Mayne Pharma veräußert.
Neuer Schwerpunkt
Seitdem widmet sich Tapestry der Entwicklung einer neuen Generation von Taxanen, die nicht nur wirksamer sein sollen, sondern auch weniger Nebenwirkungen aufweisen und bei Patienten angewendet werden können, die auf einen Behandlung mit Paclitaxel und vergleichbaren Präparaten aufgrund von resistenzen nicht mehr ansprechen. Der aussichtsreiche Produktkandidat von Tapestry trägt den Forschungsnamen TPI 287. In verschiedenen klinischen Studien wird derzeit dessen potenzial bei der Behandlung von Lungen-, Brust- und Prostatakrebs ausgelotet. Bis ende des Jahres sollen die ergebnisse der Phase-I-Tests veröffentlicht werden. Fallen diese positiv aus, dürfte dies der Aktie einen ordentlichen Schub geben.
Hohes Risioko, große Chance
Der Markt für Taxane zur Krebstherapie wird von Experten auf rund drei milliarden Dollar geschätzt. Verläuft die Entwicklung der produktkandidaten weiter positiv, dürfte sich Tapestry von diesen Kuchen eine gute Scheibe abschneiden. Allerdings befinden sich die Wirkstoffe noch in einem sehr frühen Entwicklundsstadium, was die Gefahr von rückschlägen deutlich erhöht. die Aktie ist deshalb nur für Anleger mit extremen hoher Risikobereitschaft geeignet.
WKN: A0JC4R
ISIN: US8760312046
Kürzel: TPPH ( New York)
MK: 31,4 Mio. US-$
Akt. Kurs: 1,48 Euro
Videotext: BR 542
Quelle: Der Aktionär/ Ausgabe 46
Taxane: Als Taxanen bezeichnet man chemische Substanzen, die bösartige Zellen schädigen und deren Wachstum verhindern. Taxane werden zur Bekämpfung von Krebs seit rund 10 jahren in der Chemotherapie verwendet. Paclitaxel, das aus der Rinde der pazifischen Eibe gewonnen wird, wurde als erstes Taxan genutzt.
Tapestry to Present at The Rodman & Renshaw 8th Annual Healthcare Conference on Tuesday, November 7th
2006-11-06 08:00 ET - News Release
BOULDER, Colo., Nov. 6 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. today announced that Leonard P. Shaykin, Chairman and Chief Executive Officer of Tapestry, will present an overview of the Company's progress at the Rodman & Renshaw 8th Annual Healthcare Conference on Tuesday November 7, 2006 at 3:30 PM Eastern Standard Time at the Palace Hotel in New York. A live audio webcast of the presentation may be accessed through Tapestry's website at www.tapestrypharma.com. A replay of the webcast will be available for 90 days.
About Tapestry Pharmaceuticals, Inc.
Tapestry Pharmaceuticals, Inc. is a company focused on the development of proprietary therapies for the treatment of cancer.
For more information about Tapestry and its technologies, visit Tapestry's web site at www.tapestrypharma.com.
Tapestry Pharmaceuticals, Inc.
CONTACT: Gordon Link, Senior Vice President, Chief Financial Officer,
+1-303-516-8500, glink@tapestrypharma.com, Tapestry Pharmaceuticals, Inc.;
Investor, Kevin Theiss, CEOcast, Inc., +1-212-732-4300; Media, Peter
Steinerman, +1-516-374-3031
Web site: http://www.tapestrypharma.com/
2006-11-06 08:00 ET - News Release
BOULDER, Colo., Nov. 6 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. today announced that Leonard P. Shaykin, Chairman and Chief Executive Officer of Tapestry, will present an overview of the Company's progress at the Rodman & Renshaw 8th Annual Healthcare Conference on Tuesday November 7, 2006 at 3:30 PM Eastern Standard Time at the Palace Hotel in New York. A live audio webcast of the presentation may be accessed through Tapestry's website at www.tapestrypharma.com. A replay of the webcast will be available for 90 days.
About Tapestry Pharmaceuticals, Inc.
Tapestry Pharmaceuticals, Inc. is a company focused on the development of proprietary therapies for the treatment of cancer.
For more information about Tapestry and its technologies, visit Tapestry's web site at www.tapestrypharma.com.
Tapestry Pharmaceuticals, Inc.
CONTACT: Gordon Link, Senior Vice President, Chief Financial Officer,
+1-303-516-8500, glink@tapestrypharma.com, Tapestry Pharmaceuticals, Inc.;
Investor, Kevin Theiss, CEOcast, Inc., +1-212-732-4300; Media, Peter
Steinerman, +1-516-374-3031
Web site: http://www.tapestrypharma.com/
Tapestry Reports Third Quarter 2006 Financial Results
2006-11-06 08:00 ET - News Release
BOULDER, Colo., Nov. 6 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 27, 2006.
The operating loss for the third quarter of 2006 was $3.8 million compared to an operating loss of $4.7 million for the third quarter of 2005. The net loss for the third quarter of 2006 was $3.6 million, or $0.24 per share. This compares to a net loss for the third quarter of 2005 of $5.5 million, or $1.62 per share. The third quarter 2006 operating loss includes a non-cash compensation expense of $593,000 related to the Company's implementation in 2006 of SFAS 123(R), which requires the expensing of employee stock options.
As of September 27, 2006, Tapestry had $28.2 million in cash, cash equivalents, and short-term investments.
"We have focused virtually all of our monthly cash spend on advancing our lead compound, TPI 287, a third generation proprietary taxane, into broad clinical development against a number of drug resistant solid tumors," commented Leonard P. Shaykin, Chairman and Chief Executive Officer of Tapestry Pharmaceuticals.
"Having reached MTD (the maximum tolerated dose) in our once every 21 day Phase I trial, the company is moving expeditiously to initiate our first Phase II trials at identified participating clinical sites. Additional patients are currently being added to our 21 day Phase I protocol at MTD to give us more clinical experience with the compound at this dosing schedule. We continue to escalate in the weekly times three Phase I dosing regime to reach MTD. We hope to present the data from both of these Phase I studies at the next ASCO meeting in June 2007," added Mr. Shaykin.
"We expect to begin treating patients in our first Phase II trials of TPI 287 in both prostate and non-small cell lung cancer in the first quarter of next year. Additional Phase II studies in other indications will follow shortly thereafter. Since our compound is a taxane, and active preclinically in many resistant solid tumor cell lines, our Phase II program is designed to determine in what tumor type our compound should be advanced for Phase III studies. As we recruit patients for these multiple Phase II studies we will see an increase in our clinical spending."
About Tapestry Pharmaceuticals, Inc.
Tapestry Pharmaceuticals, Inc. is a company focused on the development of proprietary therapies for the treatment of cancer.
For more information about Tapestry and its technologies, visit Tapestry's web site at www.tapestrypharma.com.
About TPI 287
TPI 287, a proprietary third generation taxane, is Tapestry's lead clinical compound. This compound was designed to overcome multi-drug resistance in solid tumors that have become resistant to taxane therapy. In preclinical testing, TPI 287 demonstrated the ability to inhibit tumor cell growth in a number of in vitro cell lines and has shown inhibition of human tumors in certain animal xenograft models when tested against standard comparative agents. The in vitro activity was seen across multiple cell lines including cell lines known to be sensitive to taxanes and cell lines known to be resistant to taxanes. In in vivo testing TPI 287 demonstrated reduction in the rate of tumor growth in both taxane resistant and taxane sensitive breast cancer xenografts. Taxane sensitive cell lines in which TPI 287 has shown activity include cell lines derived from breast cancer, uterine cancer and non-small cell lung cancer. Taxane resistant cell lines in which TPI 287 has shown activity include lines derived from breast cancer, colon cancer, prostate cancer and pancreatic cancer.
TPI 287 is currently in two Phase I studies in the United States and overseas to determine the safety and pharmacokinetic profile of the compound. A number of Phase II studies are planned in several tumor types. Tapestry plans to initiate Phase II trials in the first quarter of 2007.
Forward Looking Statements
Statements in this press release that are not historical facts are "forward-looking statements" that involve risks and uncertainties. Forward- looking statements can be identified by the use of words such as "opportunities," "trends," "potential," "estimates," "may," "will," "should," "anticipates," "expects," "hopes" or comparable terminology or by discussions of strategy. Such forward looking statements include statements relating to the presentation of data from Phase I studies at the ASCO meeting in June, the initiation of Phase II trials of TPI 287 in prostate and non-small cell lung cancer in the first quarter of 2007, to be followed by other Phase II studies shortly thereafter, and the increase in the Company's clinical spending as a result of patient recruitment in these Phase II studies. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include risks that clinical trials for TPI 287 will be delayed due to institutional approvals, patient recruitment, formulation and manufacturing difficulties, delays in finalizing and receiving approval of Phase II protocols, negotiations with regulatory agencies, or other factors; that human clinical trials may show that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that we are blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that we are limited in our ability to obtain, maintain and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development. Additional risks, uncertainties and other factors are identified under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Company's reports filed from time to time with the Securities and Exchange Commission, including its Quarter Reports on Form 10-Q for the Quarters ended June 28, 2006 and September 27, 2006. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.
For further information, please contact Gordon Link, Senior Vice President, Chief Financial Officer, at 303 516 8500.
Tapestry Pharmaceuticals, Inc.
Balance Sheets
(In thousands)
(Unaudited)
September 27, December 28,
2006 2005
ASSETS
Current assets:
Cash and cash equivalents $ 839 $ 534
Short-term investments 27,371 13,552
Prepaid expense and other current assets 419 646
Total current assets 28,629 14,732
Property, plant and equipment, net 465 608
Investment in ChromaDex, Inc. 451 451
Other assets 664 683
Total assets $ 30,209 $ 16,474
LIABILITIES AND STOCKHOLDERS' EQUITY
Total current liabilities $ 3,386 $ 3,105
Notes payable-long term, net 1,384 2,483
Total stockholders' equity 25,439 10,886
Total liabilities and stockholders' equity $ 30,209 $ 16,474
Tapestry Pharmaceuticals, Inc.
Statements of Operations
(In thousands, except per share data)
(Unaudited)
Three-Months Ended Nine-Months Ended
Sept. 27, Sept. 28, Sept. 27, Sept. 28,
2006 2005 2006 2005
Operating expenses:
Research and development $ 2,259 $ 3,139 $ 7,464 $ 8,718
General and administrative 1,575 1,530 5,070 4,596
Operating loss 3,834 4,669 12,534 13,314
Other income(expense):
Interest and other income 400 274 936 656
Interest and other expense (124) (140) (427) (447)
Impairment charges -- (963) -- (1,067)
Loss from continuing
operations (3,558) (5,498) (12,025) (14,172)
Loss from discontinued
operations -- (43) (88) (347)
Net Loss $ (3,558) $ (5,541) $(12,113) $ (14,519)
Basic and diluted loss per
share from continuing
operations $ (0.24) $ (1.61) $ (1.95) $ (4.18)
Basic and diluted loss per
share from discontinued
operations $ -- $ (0.01) $ (0.01) $ (0.10)
Basic and diluted loss per
share $ (0.24) $ (1.62) $ (1.96) $ (4.28)
Basic and diluted weighted
average shares
outstanding 15,051,659 3,423,899 6,178,875 3,393,982
Tapestry Pharmaceuticals, Inc.
CONTACT: Gordon Link, Senior Vice President, Chief Financial Officer,
+1-303-516-8500, glink@tapestrypharma.com, Tapestry Pharmaceuticals, Inc.;
Investor, Andrew Hellman, CEOcast, Inc., +1-212-732-4300; Media, Peter
Steinerman, +1-516-374-3031
Web site: http://www.tapestrypharma.com/
2006-11-06 08:00 ET - News Release
BOULDER, Colo., Nov. 6 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 27, 2006.
The operating loss for the third quarter of 2006 was $3.8 million compared to an operating loss of $4.7 million for the third quarter of 2005. The net loss for the third quarter of 2006 was $3.6 million, or $0.24 per share. This compares to a net loss for the third quarter of 2005 of $5.5 million, or $1.62 per share. The third quarter 2006 operating loss includes a non-cash compensation expense of $593,000 related to the Company's implementation in 2006 of SFAS 123(R), which requires the expensing of employee stock options.
As of September 27, 2006, Tapestry had $28.2 million in cash, cash equivalents, and short-term investments.
"We have focused virtually all of our monthly cash spend on advancing our lead compound, TPI 287, a third generation proprietary taxane, into broad clinical development against a number of drug resistant solid tumors," commented Leonard P. Shaykin, Chairman and Chief Executive Officer of Tapestry Pharmaceuticals.
"Having reached MTD (the maximum tolerated dose) in our once every 21 day Phase I trial, the company is moving expeditiously to initiate our first Phase II trials at identified participating clinical sites. Additional patients are currently being added to our 21 day Phase I protocol at MTD to give us more clinical experience with the compound at this dosing schedule. We continue to escalate in the weekly times three Phase I dosing regime to reach MTD. We hope to present the data from both of these Phase I studies at the next ASCO meeting in June 2007," added Mr. Shaykin.
"We expect to begin treating patients in our first Phase II trials of TPI 287 in both prostate and non-small cell lung cancer in the first quarter of next year. Additional Phase II studies in other indications will follow shortly thereafter. Since our compound is a taxane, and active preclinically in many resistant solid tumor cell lines, our Phase II program is designed to determine in what tumor type our compound should be advanced for Phase III studies. As we recruit patients for these multiple Phase II studies we will see an increase in our clinical spending."
About Tapestry Pharmaceuticals, Inc.
Tapestry Pharmaceuticals, Inc. is a company focused on the development of proprietary therapies for the treatment of cancer.
For more information about Tapestry and its technologies, visit Tapestry's web site at www.tapestrypharma.com.
About TPI 287
TPI 287, a proprietary third generation taxane, is Tapestry's lead clinical compound. This compound was designed to overcome multi-drug resistance in solid tumors that have become resistant to taxane therapy. In preclinical testing, TPI 287 demonstrated the ability to inhibit tumor cell growth in a number of in vitro cell lines and has shown inhibition of human tumors in certain animal xenograft models when tested against standard comparative agents. The in vitro activity was seen across multiple cell lines including cell lines known to be sensitive to taxanes and cell lines known to be resistant to taxanes. In in vivo testing TPI 287 demonstrated reduction in the rate of tumor growth in both taxane resistant and taxane sensitive breast cancer xenografts. Taxane sensitive cell lines in which TPI 287 has shown activity include cell lines derived from breast cancer, uterine cancer and non-small cell lung cancer. Taxane resistant cell lines in which TPI 287 has shown activity include lines derived from breast cancer, colon cancer, prostate cancer and pancreatic cancer.
TPI 287 is currently in two Phase I studies in the United States and overseas to determine the safety and pharmacokinetic profile of the compound. A number of Phase II studies are planned in several tumor types. Tapestry plans to initiate Phase II trials in the first quarter of 2007.
Forward Looking Statements
Statements in this press release that are not historical facts are "forward-looking statements" that involve risks and uncertainties. Forward- looking statements can be identified by the use of words such as "opportunities," "trends," "potential," "estimates," "may," "will," "should," "anticipates," "expects," "hopes" or comparable terminology or by discussions of strategy. Such forward looking statements include statements relating to the presentation of data from Phase I studies at the ASCO meeting in June, the initiation of Phase II trials of TPI 287 in prostate and non-small cell lung cancer in the first quarter of 2007, to be followed by other Phase II studies shortly thereafter, and the increase in the Company's clinical spending as a result of patient recruitment in these Phase II studies. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include risks that clinical trials for TPI 287 will be delayed due to institutional approvals, patient recruitment, formulation and manufacturing difficulties, delays in finalizing and receiving approval of Phase II protocols, negotiations with regulatory agencies, or other factors; that human clinical trials may show that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that we are blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that we are limited in our ability to obtain, maintain and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development. Additional risks, uncertainties and other factors are identified under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Company's reports filed from time to time with the Securities and Exchange Commission, including its Quarter Reports on Form 10-Q for the Quarters ended June 28, 2006 and September 27, 2006. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.
For further information, please contact Gordon Link, Senior Vice President, Chief Financial Officer, at 303 516 8500.
Tapestry Pharmaceuticals, Inc.
Balance Sheets
(In thousands)
(Unaudited)
September 27, December 28,
2006 2005
ASSETS
Current assets:
Cash and cash equivalents $ 839 $ 534
Short-term investments 27,371 13,552
Prepaid expense and other current assets 419 646
Total current assets 28,629 14,732
Property, plant and equipment, net 465 608
Investment in ChromaDex, Inc. 451 451
Other assets 664 683
Total assets $ 30,209 $ 16,474
LIABILITIES AND STOCKHOLDERS' EQUITY
Total current liabilities $ 3,386 $ 3,105
Notes payable-long term, net 1,384 2,483
Total stockholders' equity 25,439 10,886
Total liabilities and stockholders' equity $ 30,209 $ 16,474
Tapestry Pharmaceuticals, Inc.
Statements of Operations
(In thousands, except per share data)
(Unaudited)
Three-Months Ended Nine-Months Ended
Sept. 27, Sept. 28, Sept. 27, Sept. 28,
2006 2005 2006 2005
Operating expenses:
Research and development $ 2,259 $ 3,139 $ 7,464 $ 8,718
General and administrative 1,575 1,530 5,070 4,596
Operating loss 3,834 4,669 12,534 13,314
Other income(expense):
Interest and other income 400 274 936 656
Interest and other expense (124) (140) (427) (447)
Impairment charges -- (963) -- (1,067)
Loss from continuing
operations (3,558) (5,498) (12,025) (14,172)
Loss from discontinued
operations -- (43) (88) (347)
Net Loss $ (3,558) $ (5,541) $(12,113) $ (14,519)
Basic and diluted loss per
share from continuing
operations $ (0.24) $ (1.61) $ (1.95) $ (4.18)
Basic and diluted loss per
share from discontinued
operations $ -- $ (0.01) $ (0.01) $ (0.10)
Basic and diluted loss per
share $ (0.24) $ (1.62) $ (1.96) $ (4.28)
Basic and diluted weighted
average shares
outstanding 15,051,659 3,423,899 6,178,875 3,393,982
Tapestry Pharmaceuticals, Inc.
CONTACT: Gordon Link, Senior Vice President, Chief Financial Officer,
+1-303-516-8500, glink@tapestrypharma.com, Tapestry Pharmaceuticals, Inc.;
Investor, Andrew Hellman, CEOcast, Inc., +1-212-732-4300; Media, Peter
Steinerman, +1-516-374-3031
Web site: http://www.tapestrypharma.com/
Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting
3/14/2007
BOULDER, Colo., March 14, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH) today announced that it will present new data at the 2007 American Association for Cancer Research (AACR) Annual Meeting, April 14-18 in Los Angeles, Calif. Scientists from Tapestry Pharmaceuticals will discuss preclinical data on the Company's lead compound, TPI 287, in a poster presentation entitled, "TPI 287 crosses the blood brain barrier and contributes to antitumor activity in the U251 glioblastoma intracranial tumor model in nude mice." The poster (#1441) will be presented Sunday, April 15, 2007 from 1:00 - 5:00 p.m. at the Experimental and Molecular Therapeutics 8 session.
About TPI 287
TPI 287, a proprietary next generation taxane, is Tapestry's lead clinical compound. This compound was designed to overcome multi-drug resistance in solid tumors that have become resistant to taxane therapy. In preclinical testing, TPI 287 demonstrated the ability to inhibit tumor cell growth in a number of in vitro cell lines and in general, has shown equivalent inhibition of tumors in certain animal xenograft models when tested against standard comparative agents. In some cell lines resistant to taxanes, TPI 287 has demonstrated greater inhibition of tumors in certain animal xenograft models when tested against standard comparative agents. The in vitro activity was seen across multiple cell lines including cell lines known to be sensitive to taxanes and cell lines known to be resistant to taxanes. Taxane sensitive cell lines in which TPI 287 has shown activity include cell lines derived from breast cancer, uterine cancer and non-small cell lung cancer. Taxane resistant cell lines in which TPI 287 shows greater activity include lines derived from breast and colon cancer. In in vivo testing TPI 287 demonstrated greater tumor growth inhibition activity in tumor cell lines with multiple drug resistance, MDR1.
TPI 287 is currently in clinical studies in the United States. Tapestry plans to initiate multiple Phase II trials for TPI 287 in 2007.
About Tapestry Pharmaceuticals, Inc.
Tapestry Pharmaceuticals, Inc. is a company focused on the development of proprietary therapies for the treatment of cancer. For more information about Tapestry and its technologies, visit Tapestry's web site at www.tapestrypharma.com.
Forward-Looking Statements
Statements in this press release that are not historical facts are "forward-looking statements" that involve risks and uncertainties. Forward- looking statements can be identified by the use of words such as "opportunities," "trends," "potential," "estimates," "may," "will," "should," "anticipates," "expects," "hopes" or comparable terminology or by discussions of strategy. Such forward-looking statements include the statements that the Company will initiate Phase II intravenous studies of TPI 287 into the clinic in 2007. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include risks that clinical trials for TPI 287 will be delayed due to institutional approvals, patient recruitment, formulation and manufacturing difficulties, delays in finalizing and receiving approval of Phase II protocols, negotiations with regulatory agencies, or other factors; that human clinical trials may show that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that we are blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that we are limited in our ability to obtain, maintain and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development. Additional risks, uncertainties and other factors are identified under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Company's reports filed from time to time with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 27, 2006. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.
Contact: Tapestry Pharmaceuticals, Inc.
Gordon Link
Senior Vice President, Chief Financial Officer
303-516-8500
glink@tapestrypharma.com
Elma Hawkins, Ph.D.
Communications and Corporate Development
212-400-3019
ehawkins@tapestrypharma.com
Investor: Lilian Stern
Stern Investor Relations, Inc.
212-362-1200
lilian@sternir.com
Media: Lloyd Benson/Dana Conti
Schwartz Communications
781-684-0770
tapestry@schwartz-pr.com
SOURCE Tapestry Pharmaceuticals, Inc.
Gordon Link, Senior Vice President, Chief Financial Officer, +1-303-516-8500,
glink@tapestrypharma.com, or Elma Hawkins, Ph.D., Communications and Corporate
Development, +1-212-400-3019, ehawkins@tapestrypharma.com, both of Tapestry
Pharmaceuticals, Inc., or Lilian Stern, Stern Investor Relations, Inc.,
+1-212-362-1200, lilian@sternir.com, or Lloyd Benson or Dana Conti, Schwartz
Communications, +1-781-684-0770, tapestry@schwartz-pr.com
http://www.tapestrypharma.com
Copyright (C) 2007 PR Newswire. All rights reserved
3/14/2007
BOULDER, Colo., March 14, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH) today announced that it will present new data at the 2007 American Association for Cancer Research (AACR) Annual Meeting, April 14-18 in Los Angeles, Calif. Scientists from Tapestry Pharmaceuticals will discuss preclinical data on the Company's lead compound, TPI 287, in a poster presentation entitled, "TPI 287 crosses the blood brain barrier and contributes to antitumor activity in the U251 glioblastoma intracranial tumor model in nude mice." The poster (#1441) will be presented Sunday, April 15, 2007 from 1:00 - 5:00 p.m. at the Experimental and Molecular Therapeutics 8 session.
About TPI 287
TPI 287, a proprietary next generation taxane, is Tapestry's lead clinical compound. This compound was designed to overcome multi-drug resistance in solid tumors that have become resistant to taxane therapy. In preclinical testing, TPI 287 demonstrated the ability to inhibit tumor cell growth in a number of in vitro cell lines and in general, has shown equivalent inhibition of tumors in certain animal xenograft models when tested against standard comparative agents. In some cell lines resistant to taxanes, TPI 287 has demonstrated greater inhibition of tumors in certain animal xenograft models when tested against standard comparative agents. The in vitro activity was seen across multiple cell lines including cell lines known to be sensitive to taxanes and cell lines known to be resistant to taxanes. Taxane sensitive cell lines in which TPI 287 has shown activity include cell lines derived from breast cancer, uterine cancer and non-small cell lung cancer. Taxane resistant cell lines in which TPI 287 shows greater activity include lines derived from breast and colon cancer. In in vivo testing TPI 287 demonstrated greater tumor growth inhibition activity in tumor cell lines with multiple drug resistance, MDR1.
TPI 287 is currently in clinical studies in the United States. Tapestry plans to initiate multiple Phase II trials for TPI 287 in 2007.
About Tapestry Pharmaceuticals, Inc.
Tapestry Pharmaceuticals, Inc. is a company focused on the development of proprietary therapies for the treatment of cancer. For more information about Tapestry and its technologies, visit Tapestry's web site at www.tapestrypharma.com.
Forward-Looking Statements
Statements in this press release that are not historical facts are "forward-looking statements" that involve risks and uncertainties. Forward- looking statements can be identified by the use of words such as "opportunities," "trends," "potential," "estimates," "may," "will," "should," "anticipates," "expects," "hopes" or comparable terminology or by discussions of strategy. Such forward-looking statements include the statements that the Company will initiate Phase II intravenous studies of TPI 287 into the clinic in 2007. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include risks that clinical trials for TPI 287 will be delayed due to institutional approvals, patient recruitment, formulation and manufacturing difficulties, delays in finalizing and receiving approval of Phase II protocols, negotiations with regulatory agencies, or other factors; that human clinical trials may show that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that we are blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that we are limited in our ability to obtain, maintain and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development. Additional risks, uncertainties and other factors are identified under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Company's reports filed from time to time with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 27, 2006. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.
Contact: Tapestry Pharmaceuticals, Inc.
Gordon Link
Senior Vice President, Chief Financial Officer
303-516-8500
glink@tapestrypharma.com
Elma Hawkins, Ph.D.
Communications and Corporate Development
212-400-3019
ehawkins@tapestrypharma.com
Investor: Lilian Stern
Stern Investor Relations, Inc.
212-362-1200
lilian@sternir.com
Media: Lloyd Benson/Dana Conti
Schwartz Communications
781-684-0770
tapestry@schwartz-pr.com
SOURCE Tapestry Pharmaceuticals, Inc.
Gordon Link, Senior Vice President, Chief Financial Officer, +1-303-516-8500,
glink@tapestrypharma.com, or Elma Hawkins, Ph.D., Communications and Corporate
Development, +1-212-400-3019, ehawkins@tapestrypharma.com, both of Tapestry
Pharmaceuticals, Inc., or Lilian Stern, Stern Investor Relations, Inc.,
+1-212-362-1200, lilian@sternir.com, or Lloyd Benson or Dana Conti, Schwartz
Communications, +1-781-684-0770, tapestry@schwartz-pr.com
http://www.tapestrypharma.com
Copyright (C) 2007 PR Newswire. All rights reserved
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 201 | ||
| 110 | ||
| 100 | ||
| 52 | ||
| 47 | ||
| 41 | ||
| 38 | ||
| 34 | ||
| 33 | ||
| 30 |
| Wertpapier | Beiträge | |
|---|---|---|
| 30 | ||
| 25 | ||
| 25 | ||
| 24 | ||
| 16 | ||
| 15 | ||
| 14 | ||
| 13 | ||
| 11 | ||
| 10 |
